Bestatin treatment for the correction of granulocyte dysfunction in patients with recurrent furunculosis.
Bestatin, a new immunomodulator which is chemically well-defined, was examined for its capacity to enhance the phagocytic activity of neutrophilic granulocytes from patients with furunculosis. The ability of the granulocytes to ingest fluorescein-labelled yeast particles was significantly decreased in 19 patients with recurrent furunculosis (p less than 0.01). Oral administration of 40 mg bestatin to ten patients increased the phagocytic function of their granulocytes significantly (p less than 0.01).
D000328:Adult; D000368:Aged; D005260:Female; D005667:Furunculosis / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007930:Leucine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects* / Q000382:microbiology; D010587:Phagocytosis / Q000187:drug effects*; D012008:Recurrence; D013203:Staphylococcal Infections / Q000150:complications / Q000188:drug therapy
D007930:Leucine; C012211:ubenimex